---
title: "Fecal Microbiota Transplant"
subtitle: "ðŸŽ‰ 2020 (is the worst) edition ðŸŽ‰"  
author: "Brendan J. Kelly, MD, MS"
date: 'Update: `r format(Sys.Date(), "%d %B %Y")`'
output:
  xaringan::moon_reader:
    self_contained: TRUE
    lib_dir: libs
    css: xaringan-themer-plus.css
    nature:
      ratio: 16:9
      highlightStyle: github
      highlightLines: true
      countIncrementalSlides: false
---
background-image: url(svg/darkpink.svg)
background-size: 150px
background-position: 98% 90%
class: middle, inverse

```{r setup, include=FALSE}
options(htmltools.dir.version = FALSE)
```

```{r xaringan-themer, include=FALSE, warning=FALSE, eval=FALSE}
library(xaringanthemer)
style_duo_accent(
  primary_color = "#011F5B",
  secondary_color = "#990000",
  inverse_header_color = "#FFFFFF",
  header_font_google = google_font("Roboto Condensed"),
  text_font_google = google_font("Roboto"),
  code_font_google = google_font("Roboto Mono"),
  # padding = "64px 64px 64px 64px"
  # base_font_size = "24px",
  # text_font_base = "1rem",
  # header_h1_font_size = "2.75rem",
  # header_h2_font_size = "2rem",
  # header_h3_font_size = "1.25rem",
)
```

.pad-left[

### Fecal microbiota transplant (FMT) indications:  
.pad-left[
####    â‡¾ _Clostridioides difficile_ infection
]
.pad-left[
####    â‡¾ inflammatory bowel disease (IBD)  
]
.pad-left[
####    â‡¾ autologous-FMT post allogeneic-SCT  
]
### FMT regulatory oversight (& COVID-19)  
  
### Does it work? and why?  
  
]



---
background-image: url(svg/darkpink.svg)
background-size: 150px
background-position: 98% 90%
class: center, middle, inverse

# FMT indications â‡¾ CDI


---

# FMT for _Clostridioides difficile_

.center[

]



---

# C.difficile Treatment Guidelines

.pad-left[


]



---

# The FMT Backlash

.pad-left[

- Not a panacaea

- Serious adverse events

]


---

# Commercial FMT: Phase II/III Trials

.pad-left[


]


---
background-image: url(img/)
background-size: contain



---
background-image: url(svg/darkpink.svg)
background-size: 150px
background-position: 98% 90%
class: center, middle, inverse

# FMT indications â‡¾ IBD



---

# FMT for IBD Successes

.pad-left[


]


---

# FMT for IBD Adverse Events

.pad-left[

]



---

# Misclassification Matters

.pad-left[

- Lesson from FMT for CDI trials (e.g., Seres):

    - CDI diagnosed by EIA vs NAAT
    - misclassification of NAAT+ disease

- How well defined are IBD phenotypes?


]



---
background-image: url(svg/darkpink.svg)
background-size: 150px
background-position: 98% 90%
class: center, middle, inverse

# FMT indications â‡¾ allo-SCT



---

# auto-FMT for allo-SCT

.pad-left[

]


---

# Dysbiosis & Death

.pad-left[



]



---
background-image: url(img/taur_diversity_vs_engraftment.png)
background-size: 800px
background-position: 50% 50%


.footnote[Taur et al _Sci Trans Med_ 2018]


---

# Feasibility of auto-FMT

.pad-left[

]




---
background-image: url(svg/darkpink.svg)
background-size: 150px
background-position: 98% 90%
class: center, middle, inverse

# FMT regulation



---

# FMT Regulation pre-COVID-19

.pad-left[


]



---

# Impact of COVID-19

.pad-left[

- FDA partial hold

- Challenges with stool testing

- Slow (already slow) clinical trial enrollment


]



---
background-image: url(svg/darkpink.svg)
background-size: 150px
background-position: 98% 90%
class: center, middle, inverse

#  Does it work? and why?



---

# FMT Regulation pre-COVID-19

.pad-left[


]



---

# Impact of COVID-19

.pad-left[



]



---
class: center, middle, inverse
background-image: url(svg/conjugation.svg)
background-size: 500px
background-position: 85% 50%

# Questions?



---
background-image: url(svg/bacteria.svg)
background-size: 100px
background-position: 98% 90%
class: center, middle

# Thank you!
#### Slides available: [github.com/bjklab](https://github.com/bjklab/FMT-update-2020.git)
#### [brendank@pennmedicine.upenn.edu](brendank@pennmedicine.upenn.edu)




